ストックスクリーナーアプリを入手
27.62
1.18%
-0.33
アフターアワーズ：
27.45
-0.17
-0.62%
前日終値:
$27.95
開ける：
$28.25
24時間の取引高:
193.54K
Relative Volume:
0.58
時価総額：
$1.22B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-3.53%
1か月 パフォーマンス:
-10.06%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$27.43
$29.10
1週間の範囲:
$27.43
$30.45
52週間の値動き範囲:
$24.15
$33.32
Avalyn Pharma Inc Stock (AVLN) Company Profile
Compare AVLN vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVLN
Avalyn Pharma Inc
|
27.62 | 1.24B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Avalyn Pharma Inc (AVLN) 最新ニュース
Avalyn Pharma (NASDAQ:AVLN) Shares Gap DownTime to Sell? - MarketBeat
Avalyn Pharma Inc. Revenue Breakdown – NASDAQ:AVLN - TradingView
AVLN|Avalyn Pharma Ord Shs (Proposed)|Price:27.950|Chg%:-1.780 - TradingKey
Adam H. Golden Net Worth (2026) - GuruFocus
Enterprise value to revenue forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Price to sales forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Price to book forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Avalyn Pharma Inc (AVLN:UW): Stock Price, Quote and News - BNN Bloomberg
Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Average Rating of "Buy" from Analysts - MarketBeat
Avalyn Pharma (NASDAQ:AVLN) Shares Up 5.3%Here's Why - MarketBeat
Melissa Rhodes Net Worth (2026) - GuruFocus
Avalyn Pharma Inc.common stock (AVLN) Stock Price, News, Quote & History - FinancialContent
AVALYN PHARMA INC (AVLN) News Flow - Moomoo
Avalyn Pharma (AVLN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Enterprise value to EBIT forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Enterprise value to EBITDA forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Price to earnings forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Index - marketscreener.com
Avalyn Pharma Inc Actuals & Estimates (NASDAQ:AVLN) - TradingView
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Value Benchmark - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Growth Benchmark - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 3000E Growth Benchmark - marketscreener.com
AVLN Forecast — Price Target — Prediction for 2027 - TradingView
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell Small Cap Completeness Index - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2500 Index - marketscreener.com
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Avalyn Pharma (AVLN) Stock Chart and Price History 2026 - MarketBeat
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs - BioPharma Dive
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to S&P TMI Index - marketscreener.com
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Avalyn Pharma (AVLN) Earnings Date and Reports 2026 - MarketBeat
Avalyn Pharma (AVLN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Why is Avalyn Pharma stock surging today? By Investing.com - Investing.com UK
Avalyn Pharma stock rises on Phase 2b trial enrollment milestone By Investing.com - Investing.com Canada
Avalyn Pharma stock rises on Phase 2b trial enrollment milestone - Investing.com
Avalyn Pharma completes enrollment in pulmonary fibrosis trial - Investing.com
Avalyn Pharma completes enrollment in pulmonary fibrosis trial By Investing.com - Investing.com Australia
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis - The Manila Times
Avalyn Pharma Ord Shs (Proposed) (AVLN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead - inkl
Morgan Stanley Maintains AVALYN PHARMA INC(AVLN.US) With Buy Rating, Maintains Target Price $53 - 富途牛牛
Avalyn Pharma Inc. 2026 Q1 Financial Report and Material Risks Overview - Minichart
Avalyn Pharma 1Q Loss $26.9M >AVLN - Moomoo
Press Release: Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights - Moomoo
AVLN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalyn Pharma Inc. 1Q 2026: Net income $(26.9M), EPS $(21.83) — 10-Q Summary - TradingView
Avalyn: Q1 Earnings Snapshot - marketscreener.com
Avalyn Pharma Inc (AVLN) 財務データ
Avalyn Pharma Inc (AVLN) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):